Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Perpetual snake oil trash. Company will never amount to anything but robbing hopium holders.
I don't think they are going to PR anything that would help the stock price. There is still several months of low priced stealing to occur...
Yeah I like COYA as well. NRSN put out additional results this morning showing a positive trend that hopefully allows a successful P3 trial in ALS as well.
The papers emphasize a common theme: Inflammation.
Another interesting theme is drug delivery using targeted Exosome carriers (T-Helpers).
$COYA is another biotech following a similar path but focusing on ALS.
Yeah there are several. Most of the work has been done by Johns Hopkins. Long ways off.
https://www.pnas.org/doi/full/10.1073/pnas.1719902115
https://pubs.rsc.org/en/content/articlelanding/2022/bm/d1bm01142a
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00625/full
https://www.sciencedirect.com/science/article/pii/S2451945620305249
Surprising.
Any more research papers backing this P1 trial?
According to the FDA clinical trials website the MS trial is now recruiting. It's a couple months later than the last site update but status went from "not recruiting" to "recruiting the last couple days. No idea if the company ever PRs this as the Cleveland Clinic is running the show. Maybe the upcoming quarterly (next week or two) will mention it. Long road until trial completes. We're talking 2026 most likely.
Not any time soon there isn't
Monster potential here ... SNPX
Doc, just wondering if you are continuing to follow Tiziana and if you had any thoughts regarding their progress. Best wishes.
https://www.globenewswire.com/news-release/2024/04/18/2865243/0/en/Tiziana-Life-Sciences-Announces-New-Quantitative-PET-Imaging-Data-on-Foralumab-at-the-Annual-Meeting-of-the-American-Academy-of-Neurology.html
Just like all the alternative AD drugs that have failed in AD unfortunately.
This shell was a trading vehicle, bryostatin failed multiple times. Insiders knew this. It's all linked in my sticky.
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics
https://ir.synaptogen.com/news-releases/?qmodStoryID=7600649204374859
Totally understand. Hoping for the best!
I had kept few for ol' times sakes(that now got slashed by 1/25- post RS), so have only a piddly few left. If something good comes of this, will celebrate not in terms of $$ but for the dreaded disease.As long as Dr.Alkon is alive here I will hold, but like you no big hopes for me either. Good luck on everything runn
If I owned it, I would be looking for a possible MS trial or something similar to create a nice bump on this low float. There will be no trial readouts in 2024 or 2025 that I can see. I hope for the best with this drug, but it hasn't been investable since the trial failed well over a year ago. Jmho
Not been around for a bit, seeing that our SNPX has had an RS recently.Nice action since, maybe we dare to get our hopes up again runn,lol?
Dog pile heading to the bargain bin in short order. Book it. The masters of charletry.
Low floater now. Haven't owned in awhile. Could have a move if they ever announce the MS trial I suppose
SNPX...FREASH OFF THE SPLIT...
I noticed the SAVA results today. It’s a small play for me.
I’m still invested in some AD plays including Synaptogenix.
Some reasonably good results on Sava today so at least a few alternative plays still out there. Hoping bryostatin gets another shot on moderate AD as it seems to be the only one with a shot at halting the disease. Looks like the MS trial kicks off this month. I'm not in any of the AD plays at the moment in full disclosure.
https://www.clinicalleader.com/doc/was-fda-wrong-annovis-bio-shows-strong-data-and-no-side-effects-0001
Article regarding Annovis is from 2021. It mentions Tau- they have a Parkinson’s read out coming in next 7 weeks and AD second quarter. PD is looking interesting.
Tell it to the Cleveland Clinic. They are running the trial.
The replied to post contains my old sticky on this scam...
The racket is still the same...
Bryostatin trial finally gets registered with details. Starts this month. 20 patients. Essentially same dosing as previous AD trial with 2 cycles and a follow up 12 weeks after final dose fyi.
https://classic.clinicaltrials.gov/ct2/show/NCT06190912?term=bryostatin&draw=2&rank=1
read a lot of reviews on Cortexi: forget about it.
Anybody look at the Cortexi video? Claims to eliminate tennitus in six weeks and hint at helping als,hearing, and dementia also. Combination of Asian herbs. Regrows support cells at cochlear cells. (sp?)
This research method is known as "Barking up the wrong tree"....
Thank you. Yeah. They mentioned "Rockefeller" in W. Va multiple times.
I didn't see it but have read in the last week or so about the ultrasound waves aiding in plaque/tau reduction. What I had read had come out of West Virginia University where Bryostatin and Alkon had done much of their research so it could be a promising avenue. All that is dependent on how big of a problem plaque really is, which of course it up for debate. It's certainly interesting to follow and hopefully makes the anti-plaque drugs more effective with less side effect.
not a word about tau tangles.
Any comment on that 60 Minutes last night and the use of ultra sound to erase some of the crap?
Congrats! After years of promoting an alternative AD play, you bailed out of that one many months ago I read. Maybe a wise move. These AD plays are difficult, especially with science that is hard to grasp. All these years and still not a single drug that can reverse the decline significantly. A real shame.
Merry Christmas to you, too--and Jan. first is not a "Holy Day of Obligation" this year--at least in Philly.
Yeah. That's a shame for them. You just never know, have to always diversify, and never gamble more than one can afford to lose. There are home runs out there. Just got to keep plugging away and take profits when they come. Merry Christmas!
Discontinued everything. Tough world out there.
Bad surprise on ALVR...tough world out there.
It's had a nice move and you might be on to something. I've just never looked into that one. I did notice Neuren, which I've mentioned for years, keeps putting out great news in orphan indications and is sitting at around a 30 bagger with a similar drug to bryostatin but they turned from early AD research to orphan indications. You just never know. We missed the goal by not launching FragileX studies or even Rett IMO. GLTY
How about ALVR with 114 employees in Waltham, Ma. Posolevcel goes after six viruses. An allogeneic. Employees look impressive to me and Fido owns over 8 percent in multiple--non index--funds?
This is a post I made regarding ANVS 3-4 weeks ago Red. Keep in mind the stock has moved 50-60% since that post already.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173251789
Any comments about ANVS'S buntanetap for PD and AD. Way along in clinicals
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |